

MEDICAMEN Biotech Limited



Regd. & Corp. Office:
1506, Chiranjiv Tower,
43, Nehru Place,
New Delhi - 110019 (INDIA)

Tel.: 011 - 47589500-51 (50 Lines),
E-mail: info@medicamen.com
Web: www.medicamen.com
CIN No.: L74899DL1993PLC056594

Ref: STEX/Results/Published-2024-25

Date: 31.05.2024

To

**BSE Limited
Floor 25, P J Towers
Dalal Street
Mumbai-400001**

**National Stock Exchange of India Ltd
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex, Bandra (E)
Mumbai – 400 051**

BSE Code-531146

NSE Code: MEDICAMEQ

**Sub. : Copy of Publication for Audited Financial Results for the quarter and year ended
March 31, 2024**

Dear Sir,

Pursuant to regulation 30 & 47 of SEBI (Listing obligation and disclosure requirements) Regulations, 2015 (“the Regulations”), please find enclosed newspaper cutting with regard to the publication of extract of Audited Financial Results of the Company for the quarter and year ended on March 31, 2024 approved by the Board of Directors at their Meeting held on 29.05.2024.

The copy of the results published in the Financial Express and Jansatta dated May 30, 2024 is enclosed.

This is for your information and records.

Kindly acknowledge the receipt.

Thanking You,

Yours truly,
For Medicamen Biotech Limited

**Parul Choudhary
Company Secretary
ACS-44157**

Encl: As above.

Medicamen Biotech Ltd.
 Regd. Office: 1506, Chiranjiv Tower 43, Nehru Place, New Delhi-110019
 CIN : L74899DL 1993PLC056594
 E-mail : cs@medicamen.com, www.medicamen.com

Extracts of Standalone and Consolidated Audited Financial Results for the Quarter and Year ended on 31.03.2024

(In Lakhs)

Sl. No.	Particulars	Standalone				Consolidated	
		Quarter Ended		Year Ended		Year Ended	
		Audited 31.03.2024	Audited 31.03.2023	Audited 31.03.2024	Audited 31.03.2023	Audited 31.03.2024	Audited 31.03.2023
1	Total income from operations (net)	4555.04	3749.48	17468.88	14034.62	18163.19	14332.96
2	Net Profit/ (Loss) for the period (before tax, exceptional and/ or Extraordinary items)	372.51	464.70	1688.79	1733.28	1307.56	1704.50
3	Net Profit/ (Loss) for the period before tax (after exceptional and/or Extraordinary items)	372.51	464.70	1688.79	1733.28	1307.56	1704.50
4	Net Profit/ (Loss) for the period after tax (after exceptional and/or Extraordinary items)	310.31	404.60	1329.80	1500.20	949.40	1472.85
5	Total comprehensive income for the period (Comprising Profit/ (loss) for the period (after tax) and other Comprehensive income (after tax))	310.31	404.60	1329.80	1500.20	949.40	1472.85
6	Equity Share Capital	1271.46	1265.11	1271.46	1265.11	1271.46	1265.11
7	Reserves (excluding Revaluation Reserve as shown in the Balance Sheet of previous year)						
8	Earnings Per Share (of Rs. 10/- each) (for continuing and discontinued operation)						
	Basic:	2.45	3.25	10.50	12.04	7.50	11.82
	Diluted:	2.45	3.25	10.50	12.04	7.50	11.82

Note:

- The above Audited standalone and consolidated financial results for the quarter and year ended March 31, 2024 have been reviewed by the Audit Committee and approved by the Board of Directors of the company at its meeting held on 29th May 2024. The above results have been audited by the statutory auditors of the Company. The reports of the statutory auditors are unqualified.
- This statement has been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules there under and in terms of Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 and SEBI Circular dated July 5, 2016 and other recognized accounting practices and policies to the extent applicable.
- The Board of Directors have recommended a final dividend @ 10% on Equity Shares of Rs. 10/- each i.e. Re 1/- per Equity Share subject to approval of the members of the company in ensuing Annual General Meeting.
- The company operates only in one business segment, viz. Pharmaceuticals formulations, hence segment reporting is not applicable.
- The Earning Per Share has been calculated as per Indian Accounting Standard (Ind AS) 33 - Earning per Share.
- The figures are regrouped in previous year also, wherever considered necessary, to make them comparable.

For Medicamen Biotech Limited

Sd/-
Rahul Bishnoi
Chairman

Place: New Delhi
Date : 29.05.2024

on November 11, 2022, on slump sale basis. e) Results of these have been disclosed as results from Discontinued Operations. The detailed format of Quarterly Financial Results filed with the Stock Exchange in the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Quarterly Financial Results are available on the Stock Exchange and NSE : www.nseindia.com) and on the Company's website www.kgdenim.in. For Sakthi Sugars Limited (M. Manickam) Chairman & Managing Director (DIN : 00102233)

KG DENIM LIMITED
 Regd. Office: 1506, Chiranjiv Tower 43, Nehru Place, New Delhi-110019
 CIN : L74899DL 1993PLC056594
 E-mail : cs@medicamen.com, www.medicamen.com

Quarter & Year Ended 31st March 2024
 Rs. In Lakhs, Except EPS

Sl. No.	Particulars	Consolidated			
		Quarter ended		Year ended	
		31.03.2024 (Audited)	31.12.2023 (Unaudited)	31.03.2023 (Audited)	31.03.2024 (Audited)
1	Total income from operations (net)	6,750	6,659	9,229	26,775
2	Net Profit/ (Loss) for the period (before tax, exceptional and/ or Extraordinary items)	(1,441)	(324)	(1,755)	(3,833)
3	Net Profit/ (Loss) for the period before tax (after exceptional and/or Extraordinary items)	(1,185)	(324)	(1,755)	(3,576)
4	Net Profit/ (Loss) for the period after tax (after exceptional and/or Extraordinary items)	(790)	(241)	(1,300)	(2,573)
5	Total comprehensive income for the period (Comprising Profit/ (loss) for the period (after tax) and other Comprehensive income (after tax))	(582)	(241)	(1,193)	(2,364)
6	Equity Share Capital	2,565	2,565	2,565	2,565
7	Reserves (excluding Revaluation Reserve as shown in the Balance Sheet of previous year)				(676)
8	Earnings Per Share (of Rs. 10/- each) (for continuing and discontinued operation)	(3.37)	(0.94)	(5.18)	(9.99)
	Basic:	(3.37)	(0.94)	(5.18)	(9.99)
	Diluted:	(3.37)	(0.94)	(5.18)	(9.99)

and year ended 31st March, 2024 filed with the Stock Exchange. The detailed format of the Financial Results are available on the Bombay Stock Exchange website. The Statutory Auditors' report is unqualified. The results are prescribed under Section 133 of the Companies Act, 2013 and are subject to the audit of the statutory auditors.

The results are primarily due to lower volumes and finance costs. The global sale price vis a vis cost of production. There are certain amounts thereby indicating liquidity stress. Subsequently, trade creditors for resolving the issue by taking measures to improve the liquidity with those of current period. The results have significantly reduced with mismatch in the sale price vis a raw material cost in the current period.

For K G DENIM LIMITED
 Sd/-
 KG BAALAKRISHNAN
 Executive Chairman DIN : 00002174

MAGNA ELECTRO CASTINGS LIMITED

(CIN:L31103TZ1990PLC002836)

Regd. Off : 43, Balasundaram Road, Coimbatore 641018. Ph : 0422 - 2240109
 Website: www.magnacast.com | Email: info@magnacast.com

Statement of Audited Financial Results for the Quarter and year ended 31st March 2024

Particulars	Quarter ended			
	31.03.2024 Audited	31.12.2023 Unaudited	31.03.2023 Audited	31.03.2024 Unaudited
	1 Total Income from Operations	3,634.58	3,515.01	3,682.06
2 Net Profit for the period(Before Tax, Exceptional and/or Extraordinary items)	554.15	483.78	386.95	554.15
3 Net Profit for the period before tax(after Exceptional and/or Extraordinary items)	554.15	483.78	386.95	554.15
4 Net Profit for the period after tax(after Exceptional and/or Extraordinary items)	408.55	352.93	274.86	408.55
5 Total Comprehensive Income for the period[Comprising Profit for the period (after tax) and Other comprehensive Income (after tax)]	426.39	352.93	273.30	426.39
6 Equity Share Capital (Face Value Rs. 10/- each)	423.21	423.21	423.21	423.21
7 Reserves(excluding Revaluation reserve) as shown in the Audited Balance Sheet for the previous year	10,414.65	9,988.25	9,012.85	10,414.65
8 Earnings per Share(of Rs. 10/-each) (for continuing and discontinued operations)				
Basic:	9.65	8.34	6.49	9.65
Diluted	9.65	8.34	6.49	9.65

Note:

- The above is an extract of the detailed format of Quarterly and Yearly financial results filed with the Stock Exchange, BSE India and the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly and Yearly financial results are available on the websites of the Stock Exchange, www.bseindia.com and the Company's website www.magnacast.com.
- This statement has been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings.

KG DENIM LIMITED

Quarter & Year Ended 31/03/2024
 Rs. in lakhs

Sl. No.	Particulars	CONSOLIDATED				
		Quarter Ended		Year Ended		Year Ended
		31/03/2024 Audited	31/12/2023 Unaudited	31/03/2023 Audited	31/03/2024 Audited	31/03/2023 Audited
1	Total Income from Operations	6,750	6,659	9,229	26,775	14,332.96
2	Net Profit/ (Loss) for the period (before tax, exceptional and/ or Extraordinary items)	(1,441)	(324)	(1,755)	(3,833)	(1,704.50)
3	Net Profit/ (Loss) for the period before tax (after exceptional and/or Extraordinary items)	(1,185)	(324)	(1,755)	(3,576)	(1,704.50)
4	Net Profit/ (Loss) for the period after tax (after exceptional and/or Extraordinary items)	(790)	(241)	(1,300)	(2,573)	(1,472.85)
5	Total comprehensive income for the period (Comprising Profit/ (loss) for the period (after tax) and other Comprehensive income (after tax))	(582)	(241)	(1,193)	(2,364)	(1,472.85)
6	Equity Share Capital	2,565	2,565	2,565	2,565	1,265.11
7	Reserves (excluding Revaluation Reserve as shown in the Balance Sheet of previous year)				(676)	1,688
8	Earnings Per Share (of Rs. 10/- each) (for continuing and discontinued operation)	(3.37)	(0.94)	(5.18)	(9.99)	(10.91)
	Basic:	(3.37)	(0.94)	(5.18)	(9.99)	(10.91)
	Diluted:	(3.37)	(0.94)	(5.18)	(9.99)	(10.91)

Place : Hyderabad
Date : 29-May-2024

Managing Director
DIN: 07173955

Chartered Accountant



Medicamen Biotech Ltd.

Regd. Office: 1506, Chiranjiv Tower 43, Nehru Place, New Delhi-110019
CIN : L74899DL 1993PLC056594
E-mail : cs@medicamen.com, www.medicamen.com

Extracts of Standalone and Consolidated Audited Financial Results for the Quarter and Year ended on 31.03.2024

(In Lakhs)

Sl. No.	Particulars	Standalone				Consolidated	
		Quarter Ended		Year Ended		Year Ended	
		Audited 31.03.2024	Audited 31.03.2023	Audited 31.03.2024	Audited 31.03.2023	Audited 31.03.2024	Audited 31.03.2023
1	Total income from operations (net)	4555.04	3749.48	17468.88	14034.62	18163.19	14332.96
2	Net Profit/ (Loss) for the period (before tax, exceptional and/or Extraordinary items)	372.51	464.70	1688.79	1733.28	1307.56	1704.50
3	Net Profit/ (Loss) for the period before tax (after exceptional and/or Extraordinary items)	372.51	464.70	1688.79	1733.28	1307.56	1704.50
4	Net Profit/ (Loss) for the period after tax (after exceptional and/or Extraordinary items)	310.31	404.60	1329.80	1500.20	949.40	1472.85
5	Total comprehensive income for the period (Comprising Profit/ (loss) for the period (after tax) and other Comprehensive income (after tax))	310.31	404.60	1329.80	1500.20	949.40	1472.85
6	Equity Share Capital	1271.46	1265.11	1271.46	1265.11	1271.46	1265.11
7	Reserves (excluding Revaluation Reserve as shown in the Balance Sheet of previous year)						
8	Earnings Per Share (of Rs.10/- each) (for continuing and discontinued operation)						
	Basic:	2.45	3.25	10.50	12.04	7.50	11.82
	Diluted:	2.45	3.25	10.50	12.04	7.50	11.82

Note:

- The above Audited standalone and consolidated financial results for the quarter and year ended March 31, 2024 have been reviewed by the Audit Committee and approved by the Board of Directors of the company at its meeting held on 29th May 2024. The above results have been audited by the statutory auditors of the Company. The reports of the statutory auditors are unqualified.
- This statement has been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules there under and in terms of Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 and SEBI Circular dated July 5, 2016 and other recognized accounting practices and policies to the extent applicable.
- The Board of Directors have recommended a final dividend @ 10% on Equity Shares of Rs. 10/- each i.e. Re 1/- per Equity Share subject to approval of the members of the company in ensuing Annual General Meeting.
- The company operates only in one business segment, viz. Pharmaceuticals formulations, hence segment reporting is not applicable.
- The Earning Per Share has been calculated as per Indian Accounting Standard (Ind AS) 33 - Earning per Share.
- The figures are regrouped in previous year also, wherever considered necessary, to make them comparable.

For Medicamen Biotech Limited

Sd/
Rahul Bishnoi
Chairman

Place: New Delhi
Date : 29.05.2024

1.	Total Income from operations
2.	Net Profit (before tax, Exceptional and/or Extraordinary items)
3.	Net Profit (before tax, after Exceptional and/or Extraordinary items)
4.	Net Profit after tax (Share of Owners of the Company) (after Exceptional and/or Extraordinary items)
5.	Total Comprehensive Income (Share of Owners of the Company)
6.	Paid up Equity Share Capital ₹5/- per share)
7.	Reserves excluding Revaluation Reserve as at Balance Sheet date
8.	Earnings per share (not annualized) (Quarters)
	- Basic (in ₹)
	- Diluted (in ₹)

Notes:

- The above consolidated financial results for the quarter and year ended March 31, 2024 have been reviewed by the Audit Committee and approved by the Board of Directors of the company at its meeting held on 29th May 2024. The above results have been audited by the statutory auditors of the Company. The reports of the statutory auditors are unqualified.
- This statement has been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules there under and in terms of Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 and SEBI Circular dated July 5, 2016 and other recognized accounting practices and policies to the extent applicable.
- The Board of Directors have recommended a final dividend @ 10% on Equity Shares of Rs. 10/- each i.e. Re 1/- per Equity Share subject to approval of the members of the company in ensuing Annual General Meeting.
- The company operates only in one business segment, viz. Pharmaceuticals formulations, hence segment reporting is not applicable.
- The Earning Per Share has been calculated as per Indian Accounting Standard (Ind AS) 33 - Earning per Share.
- The figures are regrouped in previous year also, wherever considered necessary, to make them comparable.

Place : Mumbai
Date : 28 May 2024